Abstract
Background
Mesenchymal stem cell therapy in renal failure is rarely used because of low rates of cell engraftment after systemic delivery. Repeated intra-arterial cell administration may improve results; however, no current delivery method permits repeated intra-arterial infusions in a rat model. In this study, we developed an intra-arterial delivery system for repeated stem cell infusion via the aorta, catheterizing the left femoral artery to the suprarenal aorta under fluoroscopic guidance in rats with adenosine-induced renal failure.
Methods
First, we compared our intra-arterial catheter system (C group, n = 3) with tail vein injection (V group, n = 3) for engraftment efficacy, using mesenchymal stem cells from luciferase transgenic rats. Rats were infused with the cells and euthanized the following day; we performed cell-tracking experiments using a bioluminescence imaging system to assess the distribution of the infused cells. Second, we assessed the safety of the system over a 30-day period in a second group of six rats receiving infusions every 7 days.
Results
Cells infused through our delivery system efficiently engrafted into the kidney, compared with peripheral venous infusion. In five of the six rats in the safety study, the delivery system remained patent for at least 9 days (range, 9–24 days). Complications became evident only after 10 days.
Conclusion
Our intra-arterial catheter system was effective in delivering cells to the kidney and permitted repeated injection of cells.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol. 2008;8:726–36.
Ezquer ME, Ezquer FE, Arango-Rodríguez ML, Conget PA. MSC transplantation: a promising therapeutic strategy to manage the onset and progression of diabetic nephropathy. Biol Res. 2012;45:289–96.
Cai J, Yu X, Xu R, Fang Y, Qian X, Liu S, Teng J, Ding X. Maximum efficacy of mesenchymal stem cells in rat model of renal ischemia-reperfusion injury: renal artery administration with optimal numbers. PLoS One. 2014;9:e92347.
Wise AF, Ricardo SD. Mesenchymal stem cells in kidney inflammation and repair. Nephrology. 2012;7:1–10.
Schrepfer S, Deuse T, Reichenspurner H, Fishbein MP, Robbins RC, Pelletier MP. Stem cell transplantation: the lung barrier. Transpl Proc. 2007;39:573–6.
Herrera MB, Bussolati B, Bruno S, Morando L, Mauriello-Rimanazzi G, Sanavio F, Stamenkovic I, Bianocone L, Camussi G. Exogenous mesenchymal stem cells localize to the kidney by means of CD44 following acute tubular injury. Kidney Int. 2007;72:430–41.
Lee SR, Lee SH, Moon JY, Park JY, Lee D, Lim SJ, Jeong KH, Park JK, Lee TW, Ihm CG. Repeated administration of bone marrow-derived mesenchymal stem cells improved the protective effects on a remnant kidney model. Ren Fail. 2010;32:840–8.
Jespersen B, Knupp L, Norhcott CA. Femoral arterial and venous catheterization for blood sampling, drug administration and conscious blood pressure and heart rate measurements. J Vis Exp. 2012;24:3496.
Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, Benhaim P, Lorenz HP, Hedrick MH. Multi-lineage cells from human adipose tissue: implication for cell-based therapies. Tissue Eng. 2001;7:211–28.
Togel F, Yang Y, Zhang P, Hu Z, Westnfelder C. Bioluminescence imaging to monitor the in vivo distribution of administered mesenchymal stem cells in acute kidney injury. Am J Physiol Ren Physiol. 2008;295(1):F315–21.
Jung JW, Kwon M, Choi JC, Shin JW, Park IW, Choi BW, Kim JY. Familial occurrence of pulmonary embolism after intravenous, adipose tissue-derived stem cell therapy. Yonsei Med J. 2013;54:1293–6.
Otto WR, Wright NA. Mesenchymal stem cells: from experiment to clinic. Fibrogenesis Tissue Repair. 2011;8:20.
Christof W, Togel F. Protective actions of administered mesenchymal stem cells in acute kidney injury: relevance to clinical trials. Kidney Int Suppl. 2011;1:103–6.
Chen Y, Qian H, Zhu W, Zhang X, Yan Y, Ye S, Peng X, Li W, Xu W. Hepatocyte growth factor modification promotes the amelioration effects of human umbilical cord mesenchymal stem cells on rat acute kidney injury. Stem Cells Dev. 2011;20:103–13.
Togel F, Cohen A, Zhang P, Yang Y, Hu Z. Autologous and allogeneic marrow stromal cells are safe and effective for the treatment of acute kidney injury. Stem Cells Dev. 2009;18:475–85.
Cao H, Qian H, Xu W, Zhu W, Zhang X, Chen Y, Wang M, Yan Y, Xie Y. Mesenchymal stem cells derived from human umbilical cord ameliorate ischemia/reperfusion-induced acute renal failure in rats. Biotechnol Lett. 2010;32:725–32.
Acknowledgments
The authors would like to thank Ms. Hanako Goto for secretarial assistance and all personnel in the Institute for Laboratory Animal Research in The Jikei University School of Medicine. We are indebted to Dr. Jane Charbonneau for processing the manuscript. Luciferase transgenic rats were kindly donated by Prof. Eiji Kobayashi and Takumi Teratani (Jichi Medical University, Japan). This work was supported by grants from The Uehara Memorial Foundation and the Ministry of Education, Culture, Sports, Science and Technology and the Ministry of Health, Labour and Welfare of Japan.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors have declared that no conflict of interest exists.
Electronic supplementary material
Below is the link to the electronic supplementary material.
About this article
Cite this article
Katsuoka, Y., Ohta, H., Fujimoto, E. et al. Intra-arterial catheter system to repeatedly deliver mesenchymal stem cells in a rat renal failure model. Clin Exp Nephrol 20, 169–177 (2016). https://doi.org/10.1007/s10157-015-1161-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10157-015-1161-8